Xphyto sets up marketing team for the 25-minute COVID-19 RT-PCR test

Vancouver, Kgoing (22. February 2021) – XPhyto  The rapeutics Corp. (CSE: XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto”  The ofr the “Companies”), is pleased to announce that the company is building an experienced marketing team to bring its Point-of-Care SARS-CoV-2 (COVID-19) RT-PCR-Testsystems (“Covid-ID Lab “). Covid-ID Lab was created by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). XPhyto expects 3a to receive approval as a medical device manufacturer according to ISO 13485 by the end of February and European approval as a commercial in-vitro diagnostic device (CE-IVD) for Covid-ID Lab receives.

 The  go-to-market team consists of world-class clinical and pharmaceutical executives and service providers, the bring the necessary experience and expertise to the commercialization of Covid-ID Lab to advance effectively and quickly. Together, the team has decades of experience in the biotech and pharmaceuticals industry, including in the areas of management, business development, regulatory requirements, product launches, international marketing and sales, production, quality assurance and M&A. In particular, team members have grown medical diagnostic companies from inception tom reaching Managed over 500 million euros in annual sales in multinational companies.

“We are delighted to have a team with extensive expertise in commercializing medical diagnostic products.

 The  team has extensive experience from regulatory approvals to international manufacturing and sales,” said Hugh Rogers, CEO and Director of XPhyto. “As we near expected regulatory approval, business is evolving from XPhyto quickly from development to manufacture Application. We work hard to make the company the best possible to positionin order to be able to implement our business strategy. ”

Covid-ID Lab was designed as a fast, accurate and robust test system with low operating costs and high user friendliness and portability. Initial production is planned for Germany, with additional capacities in other countries to follow. Sales start in Europe is scheduled for April 2021. XPhyto is currently in discussions with potential distribution and wholesale partners in Europe and the Middle East.

XPhyto and 3a are also developing a portfolio of oral biosensor screening tests for the detection of bacterial and viral infectious diseases, including influenza A, group A streptococci, stomatitis, peri-implantitis and periodontal disease. Other pandemic-oriented biosensors are under development, particularly for H1N1 (swine flu) and H5N1 (bird flu).

 The  company plans to launch its first biosensor product in its second Annualeleventh 2021.

 The  company will provide further information and updates in due course.

 The  company neither expressly nor tacitly claim that its product has the ability to eradicate, cure or contain the COVID-19 pandemic.

about XPhyto

 The rapeutics Corp.

XPhyto

 The rapeutics Corp. is a life science Accelerator, which is focused on investing in the next generation of drug delivery, diagnostics, and new active pharmaceutical ingredients including: precise transdermal and orally soluble drug formulations, rapid, low cost infectious disease and oral health screening tests, and standardization of new active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids.

 The  company has research and development locations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

XPhyto

 The rapeutics Corp.:

Hugh Rogers, CEO and Director

Investorenanfragen:

Mr. Knox Henderson

T: 604-551-2360

E: [email protected]

Media inquiries:

MC Services AG

Julia Hofmann, Andreas Jungfer

T: +49 89 210 228 0

E: [email protected]

Forward-Looking Statements

This press release contains statements that contain forward-looking information within the meaning of applicable Canadian securities law (“forward-looking statements”). Forward-looking statements are often identified by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potentially”, “suggest” and other similar words or by statements that certain events or conditions “may” or “will” occur and include in this release the statement regarding the company’s goal to build a successful diagnostics, drug delivery and medicinal cannabis business. Forward-looking statements are only predictions based on the opinions and estimates of management at the time the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements Statements that are forecast to differ, including: that the company may fail to develop a commercial product; that selling products may not be a profitable business; that the company may not be able to scale its business; Product liability risks; Product regulation risks; general economic conditions; adverse industry events; future legal and regulatory developments; the inability to raise sufficient capital from internal and external sources and / or the inability to raise sufficient capital on favorable terms; Currency risks; Competition; international risks; and other risks that outside are under the control of the company.

 The  Group is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or for other reasons, unless this is expressly required by applicable law.

Neither the CSE nor its Market Authority (as that term is defined in the guidelines of the CSE) accepts responsibility for the adequacy or accuracy of this press release.

 The  source language (usually English) in which the original text is published is the official, authorized and legally valid version. This translation is included for better understanding.

 The  German version can be shortened or summarized. No responsibility or liability is assumed for the content, correctness, appropriateness or accuracy of this translation. From the perspective of the translator, the message does not constitute a buy or sell recommendation! Please note the original English message on www.sedar.com , www.sec.gov , www.asx.com.au/ or on the company website!

Stocks on the radar:Frequentis, Marinomed Biotech, Mayr-Melnhof, Warimpex, Mold, In fact, CA, Rosgix, Wienerberger, Zumtobel, DO&CO, Gurktaler AG VZ, Lenzing, Palfinger, Success AG, Stadlauer Malzfabrik AG, Wolford, UBM, Athos real estate, BTV AG, Oberbank AG trunk, LINDE, Palantir, GameStop, EVN, MTU Aero Engines.